P-270 - Regorafenib for metastatic colorectal cancer in community setting: a multicenter retrospective analysis in Hong Kong

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anticancer agents
Colon and Rectal Cancer
Biological Therapy
Presenter K.O. Lam
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors K.O. Lam1, K.C. Lee2, V.H.F. Lee1, H.C.K. Sze1, J.W.Y. Chiu1, R. Leung3, T. Yau1
  • 1Department Of Clinical Oncology, Lks Faculty Of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong/CN
  • 2Pamela Youde Nethesole Eastern Hospital, Hong Kong/CN
  • 3Queen Mary Hospital, Hong Kong/CN



The efficacy of regorafenib in refractory metastatic colorectal cancer has been demonstrated in two international phase III randomized controlled trials, the CORRECT and the CONCUR study, but the data in community setting is scarce. To evaluate the use of regorafenib in community setting, we perform a multicenter retrospective analysis in Hong Kong.


Patients were eligible for treatment with regorafenib if they have failed all available systemic agents including fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab if RAS wild-type tumor. Individual patient data was retrieved from the Department of Clinical Oncology and the Department of Medicine, Queen Mary Hospital and the Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong. Beside demographic, efficacy and toxicity data, pattern of prescription and treatment suspension were collected.


From July 2013 to January 2015, 28 patients were treated with regorafenib for metastatic colorectal cancer in a non-clinical trial setting. The median age of patients was 62 (Range 45-77) and most of them had good performance status (ECOG 0-1: 89.3%). Majority of patients presented with synchronous metastasis (64.3%) and had metastases involving multiple organs at the time of regorafenib treatment (92.9%). Sixty-four percent of tumors were RAS wild-type. Patients have received a median of three prior lines of treatment and the median time interval from date of first line therapy to the start of regorafenib was 24.3 months.

A total of 87 treatment cycles were prescribed in the 28 patients. Fifteen patients were started at 160mg daily and 9 of them required further dose reduction or suspension during subsequent cycles. Irrespective of the starting dose, 77% of additional dose reduction occurred at the first and second cycles. The main reason for dose reduction or treatment suspension was due to hand-foot syndrome followed by deranged liver function. For those who started at lower dose or required dose reduction during treatment, 14 of 22 patients were able to re-escalate the dose.

Adverse events of any grade occurred in all patients. There was one case of grade 4 anaemia due to per rectal bleeding but no treatment related death was observed. The commonest grade 3 non-haematologic adverse event were hand-foot syndrome (25%), elevated AST (14.3%)/ ALT (10.7%), elevated bilirubin (3.6%), hypoalbuminaemia (3.6%), fatigue (3.6%), diarrhea (3.6%) and bleeding (3.6%). The most common grade 3 haematologic adverse events were anaemia (7.1%) and thrombocytopenia (3.6%).

After a median follow-up of 4.9 months: 18 patients have progressed and the median progression-free survival was 3.2 months (95% CI 2.5-3.9 months) while 11 patients have died and the median survival was 6.1 months (95% CI: 1.4-10.9 months). Treatment response was uncommon and only 1 patient (3.6%) achieved a partial response and another 17 patients (60.7%) had stable disease at 8 weeks. Nine of nineteen patients were able to receive further systemic treatment after stopping regorafenib.


The efficacy and toxicity profile of regorafenib in the community setting were comparable to those reported in phase III clinical trials. Dose reduction and treatment interruption was common but dose re-escalation is feasible.